Slide 1: FY21 Full Year Results Presentation (ASX announcement)
ASX ANNOUNCEMENT/MEDIA RELEASE 25 MAY 2021 FY21 FULL YEAR RESULTS PRESENTATION Soft tissue regeneration company Aroa Biosurgery Limited (ASX:ARX, ‘Aroa’ or the ‘Company’) is pleased to release the attached FY21 full year results presentation that will be presented to investors at today’s Investor We
Slide 2: Aroa Biosurgery FY21 Full Year Results Presentation
AROA BIOSURGERY F Y 2 1 F u l l Ye a r R e s u l t s P r e s e n t a t i o n May 2021 | ASX: ARX
Slide 3: Important Notice and Disclaimer
IMPORTANT NOTICE AND DISCLAIMER This presentation (Presentation) is dated 25 May 2021 and has been prepared by Aroa Biosurgery Ltd, New Zealand company number 1980577, ARBN 638 867 473 (Aroa or the Company). Information in this Presentation The information in this Presentation is of a general backgr
Slide 4: Aroa at a Glance
AROA AT A GLANCE Well established high-growth soft tissue regeneration company NZ$23.1m 68% Gross Margin 4 million+ product sales FY21 on constant FY21, impacted by lower sales and FX Procedures with currency basis Aroa’s products 5 patented Regulatory Aroa ECM™ platform products Approvals Provides
Slide 5: Financial
tee oo Financial
Slide 6: Product sales
Product sales Product sales (Reported) Product sales (Constant Currency1) FY20: $21.9m FY21: $21.6m FY20: $21.9m FY21: $23.1m up 17% YoY up 6% YoY $13.9m $12.6m $11.9m $11.9m $10.0m down 10% YoY $10.0m down 8% YoY $9.0m $9.2m H1 FY20 H2 FY20 H1 FY21 H2 FY21 H1 FY20 H2 FY20 H1 FY21 H2 FY21 • Product
Slide 7: Financial Results
Financial Results Normalised Profit or Loss 1 Reported Reported Reported CC2 CC2 Commentary 2021 2020 YoY % 2021 YOY % NZ$000 NZ$000 NZ$000 • Product gross margin was impacted in H1 FY21 as a result of lower Product sales 21,575 21,924 (2) 23,123 5 product sales, but improved significantly in H2 FY2
Slide 8: Cash flows
Cash flows 2021 2020 Commentary $000 $000 Cash flows from operating activities Cash receipts from sales revenue 21,044 22,373 • Net cash outflow from operating activities of $5.0 million for Cash receipts from license fees, project fees, and grant income 2,552 3,865 FY21 compared to a net cash inflo
Slide 9: Products & Sales
tee oo Products & Sales
Slide 10: Aroa ECM Platform Technology
AROA ECM™ PLATFORM TECHNOLOGY All Aroa’s products utilise its proprietary Aroa ECM™ platform, which is a unique Extracellular Matrix (ECM) derived from sheep forestomach Laminin Collagen IV Elastin Vascular channels Collagen I & III GAG’s, hyaluronic acid, heparin sulphate Fibronectin Source Aroa EC
Slide 11: Unlocking Regenerative Healing for Everybody
UNLOCKING REGENERATIVE HEALING FOR EVERYBODY Aroa ECM technology offers leading regenerative performance at a significantly lower cost than other biologics enabling more patients to have access to the benefits of regenerative healing Price Biologics ‘Regenerative but weak’ Aroa Synthetics Products ‘
Slide 12: Aroa Product Range Addresses a Wide Range of Applications and Large Addressable Markets
AROA PRODUCT RANGE ADDRESSES A WIDE RANGE OF APPLICATIONS AND LARGE ADDRESSABLE MARKETS US TAM Sales Brand name Use case FY’18 FY‘19 FY’20 FY’21 FY’22 FY’23 Launch (USD) Channel Endoform™ Stalled complex Natural & $78m1 Aroa FY’13 wounds Antimicrobial Existing Commercial Products Ovitex Hernia $845m
Slide 13: Aroa Product Portfolio
AROA PRODUCT PORTFOLIO UNLOCKING REGENERATIVE HEALING ACROSS THE CONTINUUM OF CARE 12
Slide 14: Sales Channels
SALES CHANNELS THREE SALES CHANNELS TO MAXIMIZE AROA’S OPERATING LEVERAGE Channel Description Products Target Specialties Call point Sales force (FTE) US Commercial Endoform Physicians, WOCN’s/ RN’s Outpatient Wound 20 field, 8 Inside & 20 operations based in San Myriad Podiatric, Plastic, Centres &
Slide 15: Future
Future
Slide 16: Catalysts
CATALYSTS Aroa Direct Sales TELA Bio Post-COVID Product Synergies Momentum Fully dedicated Vaccinations expected to Complementary products for field sales team. Myriad expected to Clinical outcomes & cost improve throughout CY2021 every phase of healing & drive growth. savings driving increasing con
Slide 17: Aroa FY22 Outlook
AROA FY22 OUTLOOK NZ$30-$33m GM product sales FY22 39-53% higher than FY21 improvement • AROA is well placed for FY22 following an improved second half of FY21 and sales transition. • Focused on building our US commercial operations over next 24 months to drive revenue growth to take advantage of th
Slide 18: Q&A
Q&A
Slide 19: Contacts
CONTACTS Simon Hinsley Matt Wright Investor Relations Media m +61 401 809 653 m +61 451 896 420 shinsley@aroabio.com matt@nwrcommunications.com.au 64 Richard Pearse Drive, PO Box 107111, Auckland Airport, Auckland 2022, New Zealand Auckland 2150, New Zealand AROABIO.COM 18
Slide 20: Appendix: Reconciliation of Normalised Profit or Loss to NZ GAAP
APPENDIX Reconciliation of Normalised Profit or Loss to NZ GAAP Profit or Loss Reported Reported 2021 2020 NZ$000 NZ$000 Normalised loss before income tax (7,472) (3,886) Share based payments (2,010) (418) Transaction costs (1,607) (850) Other losses (8,013) (1,006) Loss before income tax (NZ GAAP)